NABRIVA.COM: Keyword Density Checker

Total words: 880 | 2-word phrases: 225 | 3-word phrases: 250 | 4-word phrases: 257

PAGE INFO

Title	Try to keep the title under 60 characters (0 characters)
Description	Try to keep the meta description between 50 - 160 characters (237 characters) Nabriva is a commercial-stage biopharmaceutical company engaged in the research & development of novel antibiotics to treat serious infections, with a current focus on the pleuromutilin class of antibiotics. Learn more at Nabriva.com
Keywords	Meta keywords are not recommended anymore (237 characters) Commercial stage biopharmaceutical company, medications for infectious diseases, new antibiotics, novel antibiotics
H1	H1 tag on the page (77 characters) Driven to Deliver Innovative Treatments for Patients With Infectious Diseases

#	Keyword	Frequency	Density
1	in the news	3	1.20%
2		3	1.20%
3	the news	3	1.20%
4	careers contact us	3	1.20%
5	news nabriva	2	0.80%
6	contact us careers	2	0.80%
7	newspublications careers contact	2	0.80%
8	contact us nabriva	2	0.80%
9	disclaimer contact us	2	0.80%
10	imprint disclaimer contact	2	0.80%
11	patents imprint disclaimer	2	0.80%
12	statement patents imprint	2	0.80%
13	nabriva therapeutics granted	2	0.80%
14	nabriva therapeutics	2	0.80%
15	performance shareholder information	2	0.80%
16	therapeutics granted new	2	0.80%
17	technology addon payment	2	0.80%
18	addon payment for	2	0.80%
19	xenleta® lefamulin and	2	0.80%
20	with infectious diseases	2	0.80%
21	lefamulin and contepo™	2	0.80%
22	fosfomycin by centers	2	0.80%
23	by centers for	2	0.80%
24	services in the	2	0.80%
25	© nabriva therapeutics	2	0.80%
26	medicaremedicaid services in	2	0.80%
27	share performance shareholder	2	0.80%
28	the team pipelineresearch	2	0.80%
29	home about nabriva	2	0.80%
30	about nabriva our	2	0.80%

#	Keyword	Frequency	Density
1		3	1.17%
2	in the news	3	1.17%
3	technology addon payment for	2	0.78%
4	patents imprint disclaimer contact	2	0.78%
5	© nabriva therapeutics plc	2	0.78%
6	news nabriva therapeutics	2	0.78%
7	disclaimer contact us careers	2	0.78%
8	share performance shareholder information	2	0.78%
9	imprint disclaimer contact us	2	0.78%
10	statement patents imprint disclaimer	2	0.78%
11	investors eventspresentations press releases	2	0.78%
12	nabriva therapeutics granted new	2	0.78%
13	newspublications careers contact us	2	0.78%
14	careers contact us nabriva	2	0.78%
15	xenleta® lefamulin and contepo™	2	0.78%
16	fosfomycin by centers for	2	0.78%
17	services in the news	2	0.78%
18	nabriva therapeutics plc ireland	2	0.78%
19	medicaremedicaid services in the	2	0.78%
20	therapeutics plc ireland registration	2	0.78%
21	program meet the team	2	0.78%
22	plc ireland registration no	2	0.78%
23	home about nabriva our	2	0.78%
24	quay dublin 1 ireland	2	0.78%
25	wall quay dublin 1	2	0.78%
26	north wall quay dublin	2	0.78%
27	meet the team pipelineresearch	2	0.78%
28	the team pipelineresearch fosfomycin	2	0.78%
29	2528 north wall quay	2	0.78%
30	the news nabriva	2	0.78%
31	about nabriva our products	2	0.78%
32	technologies and therapies that	1	0.39%
33	us	1	0.39%
34	the discovery development and	1	0.39%
35	commercialization of technologies and	1	0.39%
36	of technologies and therapies	1	0.39%
37	contact us	1	0.39%
38	and therapies that address	1	0.39%
39	infectious diseases contact us	1	0.39%
40	diseases contact us to	1	0.39%